search
Back to results

Effects of Flavanol-rich Dark Chocolate Consumption on Metabolic Profiles Among Obese Adults Using Metabolomics Approach

Primary Purpose

Obesity

Status
Recruiting
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Dark chocolate (20 grams) per day providing 508 mg of polyphenols
white chocolate (20 grams) with no polyphenols
Sponsored by
Universiti Putra Malaysia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obesity, Cocoa polyphenols, Dark chocolate

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Malaysian
  • Obese BMI ≥ 25.0 kg/m2
  • Not on any drug or herbal preparation, antioxidative or any drugs or dietary supplement.
  • Do not have any chronic diseases
  • Do not have allergy to cocoa
  • Age 18-45 years old.

Exclusion Criteria:

  • Non-Malaysian
  • BMI < 25.0 kg/m2
  • Smokers and alcohol drinkers
  • Participants with cardiovascular diseases, hypertension or diabetes
  • Participants taking medications that affect insulin, glucose, lipid or blood pressure levels
  • Participants taking any dietary supplements
  • Have allergy towards cocoa beverages
  • Participants who are currently involved in a weight management program

Sites / Locations

  • Universiti Putra MalaysiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

cocoa polyphenols

polyphenols free

Arm Description

21 grams of dark chocolate (289 mg polyphenols)

21 grams of white chocolate (0 mg polyphenols)

Outcomes

Primary Outcome Measures

change in insulin resistance at 12 week
Insulin resistance will be determined HOMA-IR and calculated as HOMA-IR = fasting serum x fasting blood glucose/22.5.
change in insulin sensitivity at 8 weeks
To assess insulin sensitivity, Quantitative Insulin Sensitivity Check Index (QUICKI) will be used and cutt off point of less than 0.33 indicates reduced insulin sensitivity

Secondary Outcome Measures

change in body weight at 8 weeks
Body weight will be measured in kilograms using SECA electronic scale model 703.
change in waist circumference at 8 weeks
Waist circumference will be assessed at the midpoint between the lowest rib andd the iliac crest using a non-stretchable tape measure. The measurement will be conducted twice to the nearest 0.1cm. The cutoff points for waist ciircumference by WHO expert committee on obesity in Asian and Pacific populations are >90 cm for men and >80cm fro women.
change in lipid profiles (TG, HDL-c, LDL-c, TC) at 8 weeks
Lipid profiles (TG, Cholesterol, LDL-c, and HDL-c) will be determined using commercially available kits using Architect ci8200 analyzer
change in inflammatory markers (C-reactive protein ) at 8 week
C-reactive protein will be measured using kits of human inflammatory cytokines by Enzyme Linked Inmuno Sorbent Assay from blood serum and will be expressed as mg/L.
change in oxidative stress markers (oxidized LDL) at 8 week
Levels of LDL-ox in plasma will be analysed at the beginning and the end (8 weeks) and will be expressed as mg/L.
changes in metabolomics profiles following flavanol-rich dark chocolate consumption at 8 week
Metabolomic analysis of the plasma sample will be performed using 1H-NMR platform
changes in gut microbiome status following flavanol-rich dark chocolate consumption at 8 week
metagenomic analysis of fecal samples will be analysed at the beginning and end (8 weeks)

Full Information

First Posted
April 7, 2020
Last Updated
March 23, 2022
Sponsor
Universiti Putra Malaysia
search

1. Study Identification

Unique Protocol Identification Number
NCT04347304
Brief Title
Effects of Flavanol-rich Dark Chocolate Consumption on Metabolic Profiles Among Obese Adults Using Metabolomics Approach
Official Title
Effects of Flavanol-rich Dark Chocolate Consumption on Metabolic Profiles Among Obese
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 23, 2022 (Anticipated)
Primary Completion Date
June 23, 2022 (Anticipated)
Study Completion Date
September 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universiti Putra Malaysia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Obesity has become a global issue due to its alarming high and increasing prevalence worldwide and the roles it plays in occurrence of many chronic diseases. In addition, obesity is characterized as a state of chronic, low-grade inflammation and is associated with an abnormal inflammatory response, low antioxidant capacity and reduced insulin sensitivity which lead to the generation of inflammation, oxidative stress and insulin resistance. As in Malaysia, study by National Health and Morbidity Survey Malaysia (NHMS) in 2011 and 2015 showed a continuing increase of the problem. In response to the rise of obesity prevalence, various efforts and strategies have been implemented in the past decade to combat this problem. The use of natural products as therapeutic agents in preventing metabolic disease has becoming popular. Cocoa and its products is a largely consumed food in the world. It has a very rich sources of phenolic compound. Several in vitro and in vivo studies have shown that polyphenols, with antioxidant, anti-inflammatory and anti-obesity properties, can boost energy expenditure and thermogenesis, lessen oxidative stress and inflammation while supporting weight loss management. Furthermore, the contribution of human studies especially among obese relatively limited. The popularity of chocolate and/or cocoa and its frequent consumption made it the target of many research studies, due to its favourable effects, and to the significant role it may exert on improving the obesity condition. Therefore, this study aims to investigate the effects of flavanol-rich dark chocolate consumption on metabolic profiles of obese adults using metabolomic approach.
Detailed Description
Overnutrition and sedentary lifestyle are the leading factors associated with the development of obesity. Obese adults usually are advised to make lifestyle modifications which include dietary restriction and physical activity recommendation. In addition, dietary supplements and medication such as anti-hypertensive, lipid lowering drugs are used to achieved targeted body weight of obese adult. Therefore, the confounding factors in this study namely dietary intake, physical activity, medication, supplements were controlled throughout the study. These factors including smoking were also controlled as it will affect the metabolites. Imbalance between energy intake and expenditure results in adipose tissue expansion due to excessive lipogenesis in adipose tissues. Generally, it is well accepted that adipose tissue expansion in an obese state is accompanied by elevated inflammation. Oxidative stress and pro-inflammatory processes are strongly related. Increased abdominal adipose tissue accelerates the production of pro-inflammatory cytokines which promote increased generation of ROS, both inflammation and oxidative stress play a significant role in the development of insulin resistant thus further are associated with the degree of metabolic dysfunction. It was hypothesized that cocoa flavanol with the properties of anti-inflammation, anti-oxidative and antiobesity properties may reduce the oxidative stress and inflammation, subsequently reduce the insulin resistance and thus improved the outcome measurements in obese adult. In order to measures the altered metabolite in the urine and blood serum following cocoa rich flavanol consumption in dark chocolate in obese adult, a metabolomics based approach is used in this study. This study is a randomized, open-labelled, parallel controlled trial where the intervention group will receive 20 grams of dark chocolate, daily for 12 weeks while the control group will receive 20 grams of white chocolate daily for 12 weeks. Measurement will be taken including sociodemographic, anthropometric measurement, diet and physical activity questionnaire, blood and urine samples at baseline and 12 weeks of intervention. Obese male adult aged 18-45 years old will be recruited

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, Cocoa polyphenols, Dark chocolate

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A randomized, open-labelled, parallel controlled trial will be conducted in Universiti Putra Malaysia from October 2021 until December 2022 involving obese adult aged 18 - 45 years.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
74 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
cocoa polyphenols
Arm Type
Experimental
Arm Description
21 grams of dark chocolate (289 mg polyphenols)
Arm Title
polyphenols free
Arm Type
Placebo Comparator
Arm Description
21 grams of white chocolate (0 mg polyphenols)
Intervention Type
Dietary Supplement
Intervention Name(s)
Dark chocolate (20 grams) per day providing 508 mg of polyphenols
Intervention Description
subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
white chocolate (20 grams) with no polyphenols
Intervention Description
subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
Primary Outcome Measure Information:
Title
change in insulin resistance at 12 week
Description
Insulin resistance will be determined HOMA-IR and calculated as HOMA-IR = fasting serum x fasting blood glucose/22.5.
Time Frame
baseline and 8 weeks
Title
change in insulin sensitivity at 8 weeks
Description
To assess insulin sensitivity, Quantitative Insulin Sensitivity Check Index (QUICKI) will be used and cutt off point of less than 0.33 indicates reduced insulin sensitivity
Time Frame
baseline and 8 weeks
Secondary Outcome Measure Information:
Title
change in body weight at 8 weeks
Description
Body weight will be measured in kilograms using SECA electronic scale model 703.
Time Frame
baseline and 8 weeks
Title
change in waist circumference at 8 weeks
Description
Waist circumference will be assessed at the midpoint between the lowest rib andd the iliac crest using a non-stretchable tape measure. The measurement will be conducted twice to the nearest 0.1cm. The cutoff points for waist ciircumference by WHO expert committee on obesity in Asian and Pacific populations are >90 cm for men and >80cm fro women.
Time Frame
baseline and 8 weeks
Title
change in lipid profiles (TG, HDL-c, LDL-c, TC) at 8 weeks
Description
Lipid profiles (TG, Cholesterol, LDL-c, and HDL-c) will be determined using commercially available kits using Architect ci8200 analyzer
Time Frame
baseline and 8 weeks
Title
change in inflammatory markers (C-reactive protein ) at 8 week
Description
C-reactive protein will be measured using kits of human inflammatory cytokines by Enzyme Linked Inmuno Sorbent Assay from blood serum and will be expressed as mg/L.
Time Frame
baseline and 8 weeks
Title
change in oxidative stress markers (oxidized LDL) at 8 week
Description
Levels of LDL-ox in plasma will be analysed at the beginning and the end (8 weeks) and will be expressed as mg/L.
Time Frame
baseline and 8 weeks
Title
changes in metabolomics profiles following flavanol-rich dark chocolate consumption at 8 week
Description
Metabolomic analysis of the plasma sample will be performed using 1H-NMR platform
Time Frame
baseline and 8 weeks
Title
changes in gut microbiome status following flavanol-rich dark chocolate consumption at 8 week
Description
metagenomic analysis of fecal samples will be analysed at the beginning and end (8 weeks)
Time Frame
baseline and 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Malaysian Obese BMI ≥ 25.0 kg/m2 Not on any drug or herbal preparation, antioxidative or any drugs or dietary supplement. Do not have any chronic diseases Do not have allergy to cocoa Age 18-45 years old. Exclusion Criteria: Non-Malaysian BMI < 25.0 kg/m2 Smokers and alcohol drinkers Participants with cardiovascular diseases, hypertension or diabetes Participants taking medications that affect insulin, glucose, lipid or blood pressure levels Participants taking any dietary supplements Have allergy towards cocoa beverages Participants who are currently involved in a weight management program
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zulfitri Azuan Mat Daud, PhD
Phone
+60397692431
Email
zulfitri@upm.edu.my
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amin Ismail, PhD
Organizational Affiliation
Universiti Putra Malaysia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universiti Putra Malaysia
City
Seri Kembangan
State/Province
Selangor
ZIP/Postal Code
43400
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zulfitri Azuan Mat Daud, PhD
Phone
60397692431
Email
zulfitri@upm.edu.my

12. IPD Sharing Statement

Citations:
PubMed Identifier
23088297
Citation
Moazzami AA, Bondia-Pons I, Hanhineva K, Juntunen K, Antl N, Poutanen K, Mykkanen H. Metabolomics reveals the metabolic shifts following an intervention with rye bread in postmenopausal women--a randomized control trial. Nutr J. 2012 Oct 22;11:88. doi: 10.1186/1475-2891-11-88.
Results Reference
background
PubMed Identifier
10927169
Citation
Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med. 2000 May 15;28(10):1456-62. doi: 10.1016/s0891-5849(00)00252-5.
Results Reference
background
PubMed Identifier
21085649
Citation
Suhre K, Meisinger C, Doring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, Mewes HW, Hrabe de Angelis M, Wichmann HE, Kronenberg F, Adamski J, Illig T. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010 Nov 11;5(11):e13953. doi: 10.1371/journal.pone.0013953.
Results Reference
background

Learn more about this trial

Effects of Flavanol-rich Dark Chocolate Consumption on Metabolic Profiles Among Obese Adults Using Metabolomics Approach

We'll reach out to this number within 24 hrs